CN112028985A - 基因工程生长因子变异体 - Google Patents

基因工程生长因子变异体 Download PDF

Info

Publication number
CN112028985A
CN112028985A CN202010915430.1A CN202010915430A CN112028985A CN 112028985 A CN112028985 A CN 112028985A CN 202010915430 A CN202010915430 A CN 202010915430A CN 112028985 A CN112028985 A CN 112028985A
Authority
CN
China
Prior art keywords
gly
glu
val
leu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010915430.1A
Other languages
English (en)
Chinese (zh)
Inventor
辛西娅·巴姆达德
贝努瓦·J·斯马格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minerva Biotechnologies Corp
Original Assignee
Minerva Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Biotechnologies Corp filed Critical Minerva Biotechnologies Corp
Publication of CN112028985A publication Critical patent/CN112028985A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
CN202010915430.1A 2011-05-09 2012-05-08 基因工程生长因子变异体 Pending CN112028985A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161484052P 2011-05-09 2011-05-09
US61/484,052 2011-05-09
CN201280034119.XA CN103930439A (zh) 2011-05-09 2012-05-08 基因工程生长因子变异体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280034119.XA Division CN103930439A (zh) 2011-05-09 2012-05-08 基因工程生长因子变异体

Publications (1)

Publication Number Publication Date
CN112028985A true CN112028985A (zh) 2020-12-04

Family

ID=47139949

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010915430.1A Pending CN112028985A (zh) 2011-05-09 2012-05-08 基因工程生长因子变异体
CN201280034119.XA Pending CN103930439A (zh) 2011-05-09 2012-05-08 基因工程生长因子变异体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280034119.XA Pending CN103930439A (zh) 2011-05-09 2012-05-08 基因工程生长因子变异体

Country Status (8)

Country Link
US (3) US20140065113A1 (cg-RX-API-DMAC7.html)
EP (1) EP2707021B1 (cg-RX-API-DMAC7.html)
JP (5) JP2014517690A (cg-RX-API-DMAC7.html)
CN (2) CN112028985A (cg-RX-API-DMAC7.html)
AU (1) AU2012253652B2 (cg-RX-API-DMAC7.html)
CA (1) CA2835453A1 (cg-RX-API-DMAC7.html)
IL (1) IL229316B (cg-RX-API-DMAC7.html)
WO (1) WO2012154759A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117736272A (zh) * 2024-02-19 2024-03-22 四川省医学科学院·四川省人民医院 一种具有促成骨功能的生物活性多肽

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4086338A1 (en) 2011-03-17 2022-11-09 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
EP2707021B1 (en) * 2011-05-09 2024-02-21 Minerva Biotechnologies Corporation Genetically engineered growth factor variants
KR20210082547A (ko) * 2013-02-20 2021-07-05 미네르바 바이오테크놀로지 코포레이션 Ｎｍｅ 저해제 및 ｎｍｅ 저해제의 사용 방법
EP3207369A4 (en) * 2014-10-16 2018-06-13 Counsyl, Inc. Variant caller
CA3183682A1 (en) 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
CA3248038A1 (en) 2022-04-12 2023-10-19 Minerva Biotechnologies Corporation ANTI-MUC1* VARIABLE ANTIBODIES AND RELATED USES

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060228357A1 (en) * 2005-04-06 2006-10-12 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US20070009918A1 (en) * 1996-04-23 2007-01-11 President And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
US20090075926A1 (en) * 2006-12-06 2009-03-19 Bamdad Cynthia C Method for identifying and manipulating cells

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2164634T3 (es) * 1989-10-18 2002-03-01 Us Health Produccion y uso de proteina nm23-h2 humana y anticuerpos previstos a tal efecto.
US20050112607A1 (en) * 1999-01-23 2005-05-26 Bamdad Cynthia C. Rapid and sensitive detection of protein aggregation
ATE407697T1 (de) * 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
WO2001010912A1 (en) * 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
US20020169290A1 (en) * 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
WO2002036626A1 (en) * 2000-11-02 2002-05-10 Maxygen Aps Single-chain multimeric polypeptides
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2002306921A1 (en) * 2001-03-27 2002-10-08 Massachusetts Institute Of Technology Methods and products related to fgf dimerization
EP1353182A3 (en) * 2002-04-12 2004-02-04 Smithkline Beecham Corporation Method of predicting cell-based assay results using binding profiles
JP2006507256A (ja) * 2002-09-24 2006-03-02 ザ バーナム インスティチュート Ｅｐｈ受容体活性を調節する新規薬剤
US7700097B2 (en) * 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
US20050054752A1 (en) * 2003-09-08 2005-03-10 O'brien John P. Peptide-based diblock and triblock dispersants and diblock polymers
CA2553187A1 (en) * 2004-01-28 2005-08-11 Syntonix Pharmaceuticals, Inc. Heterodimeric follicle stimulating hormone-fc (fsh-fc) fusion proteins for the treatment of infertility
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
JP2011526794A (ja) * 2008-07-02 2011-10-20 エマージェント プロダクト デベロップメント シアトル， エルエルシー ＴＧＦ−βアンタゴニスト多重標的結合性分子
KR20160017117A (ko) * 2008-10-09 2016-02-15 미네르바 바이오테크놀로지 코포레이션 세포내에서 다능성을 유도하기 위한 방법
MX2011013385A (es) * 2009-06-11 2012-05-29 Minerva Biotechnologies Corp Metodos para cultivar celulas madre y celulas progenitoras.
US20130040845A1 (en) * 2010-02-16 2013-02-14 Immune Disease Institute, Inc. Method for screening receptors/ligands interactions
EP4086338A1 (en) * 2011-03-17 2022-11-09 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
EP2707021B1 (en) * 2011-05-09 2024-02-21 Minerva Biotechnologies Corporation Genetically engineered growth factor variants

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070009918A1 (en) * 1996-04-23 2007-01-11 President And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
US20060228357A1 (en) * 2005-04-06 2006-10-12 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US20090075926A1 (en) * 2006-12-06 2009-03-19 Bamdad Cynthia C Method for identifying and manipulating cells

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117736272A (zh) * 2024-02-19 2024-03-22 四川省医学科学院·四川省人民医院 一种具有促成骨功能的生物活性多肽
CN117736272B (zh) * 2024-02-19 2024-04-30 四川省医学科学院·四川省人民医院 一种具有促成骨功能的生物活性多肽

Also Published As

Publication number Publication date
US20240294590A1 (en) 2024-09-05
US20200062812A1 (en) 2020-02-27
JP2020039359A (ja) 2020-03-19
EP2707021B1 (en) 2024-02-21
JP2017061471A (ja) 2017-03-30
EP2707021A4 (en) 2015-08-05
CA2835453A1 (en) 2012-11-15
EP2707021A2 (en) 2014-03-19
AU2012253652B2 (en) 2017-07-06
US20140065113A1 (en) 2014-03-06
JP2014517690A (ja) 2014-07-24
WO2012154759A2 (en) 2012-11-15
IL229316B (en) 2020-02-27
CN103930439A (zh) 2014-07-16
JP6717725B2 (ja) 2020-07-01
WO2012154759A3 (en) 2014-05-01
AU2012253652A1 (en) 2013-11-28
JP2024056702A (ja) 2024-04-23
JP2022031824A (ja) 2022-02-22
EP2707021C0 (en) 2024-02-21
IL229316A0 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
US20240294590A1 (en) Nucleic acid encoding genetically engineered growth factor variants
JP6486686B2 (ja) 単鎖抗体及び他のヘテロ多量体
JP4035400B2 (ja) 生体内エリスロポエチン活性が増進した融合蛋白質
EP2992021B1 (en) Novel cloning, expression & purification method for the preparation of ranibizumab
KR20200119251A (ko) 트랜스페린 수용체-결합 폴리펩타이드 및 이의 용도
CN106255699B (zh) 细胞穿透肽和使用其输送生物活性物质的方法
TWI237056B (en) Fusion protein having enhanced in vivo activity of erythropoietin
CN110337444B (zh) 穿越血脑屏障的纳米药物载体
RS58839B1 (sr) Muteini lipokalina u suzama koji vezuju il-4 r alfa
AU2013365796B2 (en) Stabilized insulin-like growth factor polypeptides
CN104878064A (zh) 糖蛋白的产生
CA2893359A1 (en) Protein expression enhancing polypeptides
AU2019306821B2 (en) Solubilized apyrases, methods and use
JP2023532293A5 (cg-RX-API-DMAC7.html)
KR20200107842A (ko) 트레일 트라이머와 암표적 펩타이드를 멀티디스플레이하는 페리틴 나노케이지 및 이의 항암제로서의 용도
AU2020243073B2 (en) Recombinant CCN domain proteins and fusion proteins
CN105399832A (zh) 一种无标签单链型人源双特异性抗体及其用途
WO2022191253A1 (ja) 融合タンパク質の製造方法
EP4480964A1 (en) Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat muscular diseases
CN111479820A (zh) 重组多肽中的工程化o-糖基化及其用途
RU2825102C2 (ru) Рекомбинантные белки с доменами ccn и слитые белки
WO2013157973A1 (en) Genetically modified recombinant fibroblast growth factor (fgf1) conjugated with metal or metal oxide nanoparticles, its dna and amino acid sequences and use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination